This trial is investigating the potential of the patient’s muscle cells for the treatment of anal sphincter incontinence. The trial is being conducted at St Pauls Hospital Vancouver and The Jewish General Hospital Montréal and is sponsored by Cook Myosite a biotech pharmaceutical company. The patient’s muscle progenitor cells will be injected directly into the anal sphincter. The trial expects to enrol 30 participants by December 2014 and to conclude by December 2015. Participants will be monitored for complications and anal sphincter functions such as incontinence episodes, incontinence score and sphincter pressure.